Exploring mitochondrial functions and dysfunctions in chondrocytes: toward the identification of novel therapies for osteoarthritis

Abstract

Mitochondria are essential organelles primarily described for their vital role in producing energy through oxidative phosphorylation (OxPhos). Due to the hypoxic environment of chondrocytes and their heavy reliance on glycolysis, mitochondrial functions have long been considered of minimal relevance in these cells. However, as major suppliers of energy through the ATP they produce by OxPhos, mitochondria help to regulate the balance between anabolism and catabolism. In osteoarthritis (OA), the most prevalent joint disease, this balance is dysregulated. In addition, correlations between metabolic disorders and the risk of developing OA are also increasingly studied. In this context, mitochondrial dysfunctions in OA chondrocytes are emerging as a relevant area to propose efficient, yet unavailable, disease-modifying OA drugs (DMOADs). This narrative review examines the underlying mechanisms by which the mitochondrial functions become dysregulated in chondrocytes during OA. Drawing on up-to-date literature, it highlights how both structural and functional alterations of mitochondria contribute to OA pathology in chondrocytes. Finally, this review discusses the potential of mitochondria-targeted therapeutic strategies for OA, framed within a conceptual “repair or replace” approach.

References

[1] Margulis L. The origin of plant and animal cells. Am. Sci., 1971, 59: 230-235

[2] Cavalier-Smith T. Origin of mitochondria by intracellular enslavement of a photosynthetic purple bacterium. Proc. R. Soc. B Biol. Sci., 2006, 273: 1943-1952.

[3] Vercellino I, Sazanov LA. The assembly, regulation and function of the mitochondrial respiratory chain. Nat. Rev. Mol. Cell Biol., 2022, 23: 141-161.

[4] Wilson DF. Oxidative phosphorylation: regulation and role in cellular and tissue metabolism. J. Physiol., 2017, 595: 7023-7038.

[5] Zhou S, Cui Z, Urban JPG. Factors influencing the oxygen concentration gradient from the synovial surface of articular cartilage to the cartilage–bone interface: a modeling study. Arthritis. Rheumatol., 2004, 50: 3915-3924.

[6] Archer CW, Francis-West P. The chondrocyte. Int. J. Biochem. Cell Biol., 2003, 35: 401-404.

[7] Steinmetz JD, et al.. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. Rheumatol., 2023, 5: e508-e522.

[8] Chen D, et al.. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone. Res., 2017, 5: 16044.

[9] Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat. Rev. Rheumatol., 2012, 8: 665-673.

[10] Belluzzi E, et al.. Contribution of infrapatellar fat pad and synovial membrane to knee osteoarthritis pain. Biomed. Res. Int., 2019, 2019: 6390182.

[11] Yao Q, et al.. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Sig. Transduct. Target. Ther., 2023, 8: 56.

[12] Englund M, Roemer FW, Hayashi D, Crema MD, Guermazi A. Meniscus pathology, osteoarthritis and the treatment controversy. Nat. Rev. Rheumatol., 2012, 8: 412-419.

[13] Schulze-Tanzil G. Intraarticular ligament degeneration is interrelated with cartilage and bone destruction in osteoarthritis. Cells, 2019, 8: 990.

[14] Delplace V, et al.. Osteoarthritis: from upcoming treatments to treatments yet to come. J. Bone Spine, 2021, 88: 105206.

[15] Leifer VP, Katz JN, Losina E. The burden of OA-health services and economics. Osteoarthr. Cartil., 2022, 30: 10-16.

[16] Mao X, Fu P, Wang L, Xiang C. Mitochondria: potential targets for osteoarthritis. Front. Med., 2020, 7: 581402.

[17] Blanco FJ, Rego I, Ruiz-Romero C. The role of mitochondria in osteoarthritis. Nat. Rev. Rheumatol., 2011, 7: 161-169.

[18] Tan BG, Gustafsson CM, Falkenberg M. Mechanisms and regulation of human mitochondrial transcription. Nat. Rev. Mol. Cell. Biol., 2024, 25: 119-132.

[19] Rath S, et al.. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids. Res., 2021, 49: D1541-D1547.

[20] Chacinska A, Koehler CM, Milenkovic D, Lithgow T, Pfanner N. Importing mitochondrial proteins: machineries and mechanisms. Cell, 2009, 138: 628-644.

[21] Suomalainen A, Nunnari J. Mitochondria at the crossroads of health and disease. Cell, 2024, 187: 2601-2627.

[22] Parlakgül G, et al.. Spatial mapping of hepatic ER and mitochondria architecture reveals zonated remodeling in fasting and obesity. Nat. Commun., 2024, 15. ArticleID: 3982

[23] Wang X, et al.. Mitochondrial flashes regulate ATP homeostasis in the heart. eLife, 2017, 6: e23908.

[24] Garbincius JF, Elrod JW. Mitochondrial calcium exchange in physiology and disease. Physiol. Rev., 2022, 102: 893-992.

[25] Martin JH, Matthews JL. Mitochondrial granules in chondrocytes. Calc. Tis Res., 1969, 3: 184-193.

[26] Arsenis C. Role of mitochondria in calcification, mitochondrial activity distribution in the epiphyseal plate and accumulation of calcium and phosphate ions by chondrocyte mitochondria. Biochem. Biophys. Res. Commun., 1972, 46: 1928-1935.

[27] Blanco FJ, López-Armada MJ, Maneiro E. Mitochondrial dysfunction in osteoarthritis. Mitochondrion, 2004, 4: 715-728.

[28] Karcsú S, László FA, Tóth L, Jancsó G, Bácsy E. Calcium-containing mitochondrial granules in neurohypophysial axon terminals disappear following vasopressin treatment of Brattleboro rats. Neurosci. Lett., 1983, 39: 181-185.

[29] Akisaka T, Miyaji T, Yoshida H, Inoue M. Ultrastructure of quick-frozen and freeze-substituted chick osteoclasts. J. Anat., 1997, 190(Pt 3): 433-445.

[30] Saetersdal TS, Myklebust R, Berg Justesen NP, Engedal H, Olsen WC. Calcium containing particles in mitochondria of heart muscle cells as shown by cryo-ultramicrotomy and X-ray microanalysis. Cell. Tissue. Res., 1977, 182: 17-31.

[31] Mobasheri A, Neama G, Bell S, Richardson S, Carter SD. Human articular chondrocytes express three facilitative glucose transporter isoforms: GLUT1, GLUT3 and GLUT9. Cell Biol. Int., 2002, 26: 297-300.

[32] Ohashi Y, et al.. Metabolic reprogramming in chondrocytes to promote mitochondrial respiration reduces downstream features of osteoarthritis. Sci. Rep., 2021, 11. ArticleID: 15131

[33] Westermann B. Bioenergetic role of mitochondrial fusion and fission. Biochim. Biophys. Acta Bioenergy, 2012, 1817: 1833-1838.

[34] Brand MD, et al.. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free. Radic. Biol. Med., 2004, 37: 755-767.

[35] Muller FL, Liu Y, Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J. Biol. Chem., 2004, 279: 49064-49073.

[36] Missiroli, S., Perrone, M., Genovese, I., Pinton, P. & Giorgi, C. Cancer metabolism and mitochondria: finding novel mechanisms to fight tumours. eBioMedicine59, 102943 (2020).

[37] Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid. Redox. Signal., 2010, 12: 537-577.

[38] Kusminski CM, Scherer PE. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol. Metab., 2012, 23: 435-443.

[39] Ma C, Wang J, Hong F, Yang S. Mitochondrial dysfunction in rheumatoid arthritis. Biomolecules, 2022, 12: 1216.

[40] D’Alessandro MCB, Kanaan S, Geller M, Praticò D, Daher JPL. Mitochondrial dysfunction in Alzheimer’s disease. Ageing Res. Rev., 2025, 107: 102713.

[41] Borsche M, Pereira SL, Klein C, Grünewald A. Mitochondria and Parkinson’s disease: clinical, molecular, and translational aspects. J. Parkinsons Dis., 2021, 11: 45-60.

[42] Wu X, et al.. Dysregulated energy metabolism impairs chondrocyte function in osteoarthritis. Osteoarthr. Cartil., 2023, 31: 613-626.

[43] Wallace DC. Mitochondrial DNA variation in human radiation and disease. Cell, 2015, 163: 33-38.

[44] Dalmao-Fernández A, et al.. Mitochondrial DNA from osteoarthritic patients drives functional impairment of mitochondrial activity: a study on transmitochondrial cybrids. Cytotherapy, 2021, 23: 399-410.

[45] Fernández-Moreno M, et al.. Mitochondrial DNA haplogroups influence the risk of incident knee osteoarthritis in OAI and CHECK cohorts. A meta-analysis and functional study. Ann. Rheum. Dis., 2017, 76: 1114-1122.

[46] Scotece M, et al.. Mitochondrial DNA impact on joint damaged process in a conplastic mouse model after being surgically induced with osteoarthritis. Sci. Rep., 2021, 11. ArticleID: 9112

[47] Scotece M, et al.. mtDNA variability determines spontaneous joint aging damage in a conplastic mouse model. Aging, 2022, 14: 5966-5983.

[48] Blanco FJ, Valdes AM, Rego-Pérez I. Mitochondrial DNA variation and the pathogenesis of osteoarthritis phenotypes. Nat. Rev. Rheumatol., 2018, 14: 327-340.

[49] Ramos-Louro P, et al.. mtDNA haplogroup A enhances the effect of obesity on the risk of knee OA in a Mexican population. Sci. Rep., 2022, 12. ArticleID: 5173

[50] Fang H, et al.. Role of mtDNA haplogroups in the prevalence of knee osteoarthritis in a Southern Chinese population. Int. J. Mol. Sci., 2014, 15: 2646-2659.

[51] Durán-Sotuela A, et al.. A meta-analysis and a functional study support the influence of mtDNA variant m.16519C on the risk of rapid progression of knee osteoarthritis. Ann. Rheum. Dis., 2023, 82: 974-984.

[52] Wiegertjes R, van de Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology, 2020, 59: 2681-2694.

[53] Chang M-C, et al.. Accumulation of mitochondrial DNA with 4977-bp deletion in knee cartilage-an association with idiopathic osteoarthritis. Osteoarthr. Cartil., 2005, 13: 1004-1011.

[54] Grishko VI, Ho R, Wilson GL, Pearsall AW. Diminished mitochondrial DNA integrity and repair capacity in OA chondrocytes. Osteoarthr. Cartil., 2009, 17: 107-113.

[55] Maneiro E, et al.. Mitochondrial respiratory activity is altered in osteoarthritic human articular chondrocytes. Arthritis Rheumatol., 2003, 48: 700-708.

[56] Pascarelli NA, Collodel G, Moretti E, Cheleschi S, Fioravanti A. Changes in ultrastructure and cytoskeletal aspects of human normal and osteoarthritic chondrocytes exposed to interleukin-1β and cyclical hydrostatic pressure. Int. J. Mol. Sci., 2015, 16: 26019-26034.

[57] Ansari MY, Novak K, Haqqi TM. ERK1/2-mediated activation of DRP1 regulates mitochondrial dynamics and apoptosis in chondrocytes. Osteoarthr. Cartil., 2022, 30: 315-328.

[58] Wang F-S, et al.. Irisin mitigates oxidative stress, chondrocyte dysfunction and osteoarthritis development through regulating mitochondrial integrity and autophagy. Antioxidants, 2020, 9: 810.

[59] Hu S, et al.. TBK1-medicated DRP1 phosphorylation orchestrates mitochondrial dynamics and autophagy activation in osteoarthritis. Acta Pharmacol. Sin., 2023, 44: 610-621.

[60] Yi N, et al.. Nodakenin attenuates cartilage degradation and inflammatory responses in a mice model of knee osteoarthritis by regulating mitochondrial Drp1/ROS/NLRP3 axis. Int. Immunopharmacol., 2022, 113: 109349.

[61] Kim D, et al.. Fis1 depletion in osteoarthritis impairs chondrocyte survival and peroxisomal and lysosomal function. J. Mol. Med., 2016, 94: 1373-1384.

[62] Xu L, et al.. MFN2 contributes to metabolic disorders and inflammation in the aging of rat chondrocytes and osteoarthritis. Osteoarthr. Cartil., 2020, 28: 1079-1091.

[63] Deng X, et al.. Moderate mechanical strain and exercise reduce inflammation and excessive autophagy in osteoarthritis by downregulating mitofusin 2. Life. Sci., 2023, 332: 122020.

[64] Madhu V, et al.. The loss of OPA1 accelerates intervertebral disc degeneration and osteoarthritis in aged mice. Nat. Commun., 2025, 16. ArticleID: 5996

[65] Frezza C, et al.. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell, 2006, 126: 177-189.

[66] Ansari MY, Khan NM, Ahmad I, Haqqi TM. Parkin clearance of dysfunctional mitochondria regulates ROS levels and increases survival of human chondrocytes. Osteoarthr. Cartil., 2018, 26: 1087-1097.

[67] Blanco FJ, Rego-Pérez I. Mitochondria and mitophagy: biosensors for cartilage degradation and osteoarthritis. Osteoarthr. Cartil., 2018, 26: 989-991.

[68] Xian Y, et al.. Enhanced SIRT3 expression restores mitochondrial quality control mechanism to reverse osteogenic impairment in type 2 diabetes mellitus. Bone Res., 2025, 13: 30.

[69] Chen L-Y, Wang Y, Terkeltaub R, Liu-Bryan R. Activation of AMPK-SIRT3 signaling is chondroprotective by preserving mitochondrial DNA integrity and function. Osteoarthr. Cartil., 2018, 26: 1539-1550.

[70] Zhang Y, et al.. Reprogramming of mitochondrial respiratory chain complex by targeting SIRT3-COX4I2 axis attenuates osteoarthritis progression. Adv. Sci., 2023, 10. ArticleID: e2206144

[71] Ma, Y. et al. Targeting Parkin-regulated metabolomic change in cartilage in the treatment of osteoarthritis. iScience. 27, 110597 (2024).

[72] Shin HJ, et al.. Pink1-mediated chondrocytic mitophagy contributes to cartilage degeneration in osteoarthritis. J. Clin. Med., 2019, 8: 1849.

[73] Fang G, et al.. FUNDC1/PFKP-mediated mitophagy induced by KD025 ameliorates cartilage degeneration in osteoarthritis. Mol. Ther., 2023, 31: 3594-3612.

[74] Caramés B, Taniguchi N, Otsuki S, Blanco FJ, Lotz M. Autophagy is a protective mechanism in normal cartilage and its aging-related loss is linked with cell death and osteoarthritis. Arthritis Rheumatol., 2010, 62: 791-801.

[75] Terkeltaub R, Yang B, Lotz M, Liu-Bryan R. Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1β and tumor necrosis factor α. Arthritis Rheumatol., 2011, 63: 1928-1937.

[76] Petursson F, et al.. Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes. Arthritis Res. Ther., 2013, 15: R77.

[77] Zhou S, et al.. AMPK deficiency in chondrocytes accelerated the progression of instability-induced and ageing-associated osteoarthritis in adult mice. Sci. Rep., 2017, 7. ArticleID: 43245

[78] Sun J, et al.. Sestrin2 overexpression attenuates osteoarthritis pain via induction of AMPK/PGC-1α-mediated mitochondrial biogenesis and suppression of neuroinflammation. Brain Behav. Immun., 2022, 102: 53-70.

[79] Wang Y, Zhao X, Lotz M, Terkeltaub R, Liu-Bryan R. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor γ coactivator 1. Arthritis Rheumatol., 2015, 67: 2141-2153.

[80] Lu Q, et al.. SIRT1 restoration enhances chondrocyte autophagy in osteoarthritis through PTEN-mediated EGFR ubiquitination. Cell. Death. Discov., 2022, 8: 1-10.

[81] Sacitharan PK, Bou-Gharios G, Edwards JR. SIRT1 directly activates autophagy in human chondrocytes. Cell. Death. Discov., 2020, 6: 1-8.

[82] Li Y, et al.. The expression of SIRT1 in articular cartilage of patients with knee osteoarthritis and its correlation with disease severity. J. Orthop. Surg. Res., 2016, 11: 144.

[83] Matsuzaki T, et al.. Disruption of Sirt1 in chondrocytes causes accelerated progression of osteoarthritis under mechanical stress and during ageing in mice. Ann. Rheum. Dis., 2014, 73: 1397-1404.

[84] Yamamoto T, et al.. Knee osteoarthritis progression is delayed in silent information regulator 2 ortholog 1 knock-in mice. Int. J. Mol. Sci., 2021, 22: 10685.

[85] Moon M-H, et al.. SIRT1, a class III histone deacetylase, regulates TNF-α-induced inflammation in human chondrocytes. Osteoarthr. Cartil., 2013, 21: 470-480.

[86] Oppenheimer H, et al.. 75-kd sirtuin 1 blocks tumor necrosis factor α-mediated apoptosis in human osteoarthritic chondrocytes. Arthritis Rheumatol., 2012, 64: 718-728.

[87] Ea H-K, et al.. Articular cartilage calcification in osteoarthritis: insights into crystal-induced stress. Arthritis Rheumatol., 2011, 63: 10-18.

[88] Terkeltaub R, Johnson K, Murphy A, Ghosh S. Invited review: the mitochondrion in osteoarthritis. Mitochondrion, 2002, 1: 301-319.

[89] Bernabei I, So A, Busso N, Nasi S. Cartilage calcification in osteoarthritis: mechanisms and clinical relevance. Nat. Rev. Rheumatol., 2023, 19: 10-27.

[90] Pei D-D, et al.. Contribution of Mitophagy to Cell-Mediated Mineralization: Revisiting a 50-Year-Old Conundrum. Adv. Sci. (Weinh), 2018, 5. ArticleID: 1800873

[91] Johnson K, et al.. Mitochondrial oxidative phosphorylation is a downstream regulator of nitric oxide effects on chondrocyte matrix synthesis and mineralization. Arthritis. Rheum., 2000, 43: 1560-1570.

[92] Denton RM, Randle PJ, Martin BR. Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem. J., 1972, 128: 161.

[93] Denton RM. Regulation of mitochondrial dehydrogenases by calcium ions. Biochim. Biophys. Acta., 2009, 1787: 1309-1316.

[94] Baumgartner HK, et al.. Calcium Elevation in Mitochondria Is the Main Ca2+ Requirement for Mitochondrial Permeability Transition Pore (mPTP) Opening. J. Biol. Chem., 2009, 284: 20796-20803.

[95] Héraud F, Héraud A, Harmand MF. Apoptosis in normal and osteoarthritic human articular cartilage. Ann. Rheum. Dis., 2000, 59: 959-965.

[96] Thomas CM, Fuller CJ, Whittles CE, Sharif M. Chondrocyte death by apoptosis is associated with cartilage matrix degradation. Osteoarthritis. Cartilage., 2007, 15: 27-34.

[97] Yuan H, et al.. PPARγ regulates osteoarthritis chondrocytes apoptosis through caspase-3 dependent mitochondrial pathway. Sci. Rep., 2024, 14. ArticleID: 11237

[98] Zhuang C, Ni S, Yang Z, Liu R. Oxidative stress induces chondrocyte apoptosis through caspase-dependent and caspase-independent mitochondrial pathways and the antioxidant mechanism of angelica sinensis polysaccharide. Oxid. Med. Cell. Longev., 2020, 2020: 3240820.

[99] Rottenberg H. The reduction in the mitochondrial membrane potential in aging: the role of the mitochondrial permeability transition pore. Int. J. Mol. Sci., 2023, 24: 12295.

[100] Dalmao-Fernández A, et al.. Mitochondrial role on cellular apoptosis, autophagy, and senescence during osteoarthritis pathogenesis. Cells, 2024, 13: 976.

[101] Ansari MY, et al.. Mitochondrial dysfunction triggers a catabolic response in chondrocytes via ROS-mediated activation of the JNK/AP1 pathway. J. Cell. Sci., 2020, 133: jcs247353.

[102] Scott JL, et al.. Superoxide dismutase down regulation in osteoarthritis progression and end-stage disease. Ann. Rheum. Dis., 2010, 69: 1502-1510.

[103] Koike M, et al.. SOD2 deficiency in chondrocytes accelerates age-related osteoarthritis in mice. Osteoarthr. Cartil., 2014, 22: S7.

[104] Loeser RF, et al.. Overexpression of peroxiredoxin 3 in cartilage reduces the severity of age-related osteoarthritis but not surgically induced osteoarthritis in mice. ACR. Open. Rheumatol., 2022, 4: 441-446.

[105] Han J, et al.. Moderate mechanical stress suppresses chondrocyte ferroptosis in osteoarthritis by regulating NF-κB p65/GPX4 signaling pathway. Sci. Rep., 2024, 14. ArticleID: 5078

[106] Arra M, et al.. LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis. Nat. Commun., 2020, 11. ArticleID: 3427

[107] Someya S, et al.. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell, 2010, 143: 802-812.

[108] Fu Y, et al.. Aging promotes sirtuin 3-dependent cartilage superoxide dismutase 2 acetylation and osteoarthritis. Arthritis. Rheumatol., 2016, 68: 1887-1898.

[109] Quiñonez-Flores CM, González-Chávez SA, Pacheco-Tena C. Hypoxia and its implications in rheumatoid arthritis. J. Biomed. Sci., 2016, 23: 62.

[110] Walsh DA, et al.. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology, 2010, 49: 1852-1861.

[111] Zhang H, et al.. Maintaining hypoxia environment of subchondral bone alleviates osteoarthritis progression. Sci. Adv., 2023, 9. ArticleID: eabo7868

[112] DeBerardinis RJ, Chandel NS. We need to talk about the Warburg effect. Nat. Metab., 2020, 2: 127-129.

[113] Lan W. et al. UGDH lactylation aggravates osteoarthritis by suppressing glycosaminoglycan synthesis and orchestrating nucleocytoplasmic transport to activate MAPK signaling. Adv. Sci.12, 2413709 (2025).

[114] Damyanovich AZ, Staples JR, Chan AD, Marshall KW. Comparative study of normal and osteoarthritic canine synovial fluid using 500 MHz 1H magnetic resonance spectroscopy. J. Orthop. Res., 1999, 17: 223-231.

[115] Piccionello AP, et al.. Comparative study of 1H-NMR metabolomic profile of canine synovial fluid in patients affected by four progressive stages of spontaneous osteoarthritis. Sci. Rep., 2024, 14. ArticleID: 3627

[116] Lacitignola L, Fanizzi FP, Francioso E, Crovace A. 1H NMR investigation of normal and osteo-arthritic synovial fluid in the horse. Vet. Comp. Orthop. Traumatol., 2008, 21: 85-88.

[117] Mickiewicz B, et al.. Metabolic profiling of synovial fluid in a unilateral ovine model of anterior cruciate ligament reconstruction of the knee suggests biomarkers for early osteoarthritis. J. Orthop. Res., 2015, 33: 71-77.

[118] Yang X, et al.. Pyruvate kinase M2 modulates the glycolysis of chondrocyte and extracellular matrix in osteoarthritis. DNA. Cell Biol., 2018, 37: 271-277.

[119] Li HM, et al.. Inhibition of glycolysis by targeting lactate dehydrogenase A facilitates hyaluronan synthase 2 synthesis in synovial fibroblasts of temporomandibular joint osteoarthritis. Bone, 2020, 141: 115584.

[120] Liu B, et al.. Glycolytic enzyme PKM2 regulates cell senescence but not inflammation in the process of osteoarthritis. Acta. Biochim. Biophys. Sin., 2023, 55: 1425-1433.

[121] Defois A, et al.. Osteoarthritic chondrocytes undergo a glycolysis-related metabolic switch upon exposure to IL-1b or TNF. Cell. Commun. Signal., 2023, 21. ArticleID: 137

[122] Cillero-Pastor B, Rego-Pérez I, Oreiro N, Fernandez-Lopez C, Blanco FJ. Mitochondrial respiratory chain dysfunction modulates metalloproteases -1, -3 and -13 in human normal chondrocytes in culture. BMC Musculoskelet. Disord., 2013, 14. ArticleID: 235

[123] Ma Y, et al.. Mitochondria relay cholesterol signal exacerbates osteoarthritis in mice. Nat. Commun., 2025, 16. ArticleID: 10123

[124] Zhong G, Madry H, Cucchiarini M. Mitochondrial genome editing to treat human osteoarthritis-a narrative review. Int. J. Mol. Sci., 2022, 23: 1467.

[125] Luo H, et al.. Mitochondrial transplantation: a promising strategy for treating degenerative joint diseases. J. Transl. Med., 2024, 22. ArticleID: 941

[126] Fahey M, et al.. Mesenchymal stromal cells donate mitochondria to articular chondrocytes exposed to mitochondrial, environmental, and mechanical stress. Sci. Rep., 2022, 12. ArticleID: 21525

[127] Wang R, Maimaitijuma T, Ma Y-Y, Jiao Y, Cao Y-P. Mitochondrial transfer from bone-marrow-derived mesenchymal stromal cells to chondrocytes protects against cartilage degenerative mitochondrial dysfunction in rats chondrocytes. Chin. Med. J., 2020, 134: 212-218.

[128] Court AC, et al.. Mitochondrial transfer balances cell redox, energy and metabolic homeostasis in the osteoarthritic chondrocyte preserving cartilage integrity. Theranostics, 2024, 14: 6471-6486.

[129] Yu M, Wang D, Chen X, Zhong D, Luo J. BMSCs-derived mitochondria improve osteoarthritis by ameliorating mitochondrial dysfunction and promoting mitochondrial biogenesis in chondrocytes. Stem Cell. Rev. Rep., 2022, 18: 3092-3111.

[130] Lee AR, et al.. Mitochondrial transplantation ameliorates the development and progression of osteoarthritis. Immune Netw., 2022, 22. ArticleID: e14

[131] Vega-Letter AM, et al.. Safety and efficacy of mesenchymal stromal cells mitochondria transplantation as a cell-free therapy for osteoarthritis. J. Transl. Med., 2025, 23. ArticleID: 26

[132] Pers Y-M, et al.. Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial. Ann. Rheum. Dis., 2025, 84: 2103-2114.

[133] Kim H-R, et al.. Fusogenic liposomes encapsulating mitochondria as a promising delivery system for osteoarthritis therapy. Biomaterials, 2023, 302: 122350.

[134] Emani SM, Piekarski BL, Harrild D, Del Nido PJ, McCully JD. Autologous mitochondrial transplantation for dysfunction after ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg., 2017, 154: 286-289.

[135] Guariento A, et al.. Autologous mitochondrial transplantation for cardiogenic shock in pediatric patients following ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg., 2021, 162: 992-1001.

[136] Walker, M. et al. Autologous mitochondrial transplant for acute cerebral ischemia: Phase 1 trial results and review. J. Cereb. Blood Flow Metab. 0271678X241305230 https://doi.org/10.1177/0271678X241305230 (2024).

[137] Chen P, et al.. A plant-derived natural photosynthetic system for improving cell anabolism. Nature, 2022, 612: 546-554.

[138] Pi Y, et al.. Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display. Biomaterials, 2011, 32: 6324-6332.

[139] Rothenfluh DA, Bermudez H, O’Neil CP, Hubbell JA. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat. Mater., 2008, 7: 248-254.

[140] Jiang, D., Guo, J., Liu, Y., Li, W. & Lu, D. Glycolysis: an emerging regulator of osteoarthritis. Front. Immunol. 14, 1327852 (2024).

[141] Wen Z-H, et al.. Intra-articular lactate dehydrogenase a inhibitor oxamate reduces experimental osteoarthritis and nociception in rats via possible alteration of glycolysis-related protein expression in cartilage tissue. Int. J. Mol. Sci., 2023, 24: 10770.

[142] Arra M, Swarnkar G, Alippe Y, Mbalaviele G, Abu-Amer Y. IκB-ζ signaling promotes chondrocyte inflammatory phenotype, senescence, and erosive joint pathology. Bone Res., 2022, 10: 12.

[143] Coleman MC, et al.. Targeting mitochondrial responses to intra-articular fracture to prevent posttraumatic osteoarthritis. Sci. Transl. Med., 2018, 10. ArticleID: eaan5372

[144] Han J, Kim YH, Han S. Increased oxidative phosphorylation through pyruvate dehydrogenase kinase 2 deficiency ameliorates cartilage degradation in mice with surgically induced osteoarthritis. Exp. Mol. Med., 2025, 57: 390-401.

[145] Dave M, et al.. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis. Rheum., 2008, 58: 2786-2797.

[146] Csaki C, Keshishzadeh N, Fischer K, Shakibaei M. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem. Pharmacol., 2008, 75: 677-687.

[147] Liang C, et al.. Resveratrol improves the progression of osteoarthritis by regulating the SIRT1-FoxO1 pathway-mediated cholesterol metabolism. Mediators. Inflamm., 2023, 2023: 2936236.

[148] Li W, Cai L, Zhang Y, Cui L, Shen G. Intra-articular resveratrol injection prevents osteoarthritis progression in a mouse model by activating SIRT1 and thereby silencing HIF-2α. J. Orthop. Res., 2015, 33: 1061-1070.

[149] Wei L, Pan Q, Teng J, Zhang H, Qin N. Intra-articular administration of PLGA resveratrol sustained-release nanoparticles attenuates the development of rat osteoarthritis. Mater. Today Bio, 2024, 24: 100884.

[150] Qin N, et al.. Local intra-articular injection of resveratrol delays cartilage degeneration in C57BL/6 mice by inducing autophagy via AMPK/mTOR pathway. J. Pharmacol. Sci., 2017, 134: 166-174.

[151] Nguyen C, et al.. Oral resveratrol in adults with knee osteoarthritis: a randomized placebo-controlled trial (ARTHROL). PLoS Med., 2024, 21. ArticleID: e1004440

[152] Nohara K, et al.. Nobiletin fortifies mitochondrial respiration in skeletal muscle to promote healthy aging against metabolic challenge. Nat. Commun., 2019, 10. ArticleID: 3923

[153] Amarsanaa K, Kim H-J, Ko E-A, Jo J, Jung S-C. Nobiletin exhibits neuroprotective effects against mitochondrial complex I inhibition via regulating apoptotic signaling. Exp. Neurobiol., 2021, 30: 73-86.

[154] Lee S-H, et al.. Nobiletin enhances mitochondrial function by regulating SIRT1/PGC-1α signaling in porcine oocytes during in vitro maturation. Biochem. Biophys. Res. Commun, 2024, 706. ArticleID: 149747

[155] Wang C, et al.. Protective effects of metformin against osteoarthritis through upregulation of SIRT3-mediated PINK1/Parkin-dependent mitophagy in primary chondrocytes. Biosci. Trends, 2019, 12: 605-612.

[156] Li H, et al.. Exploration of metformin as novel therapy for osteoarthritis: preventing cartilage degeneration and reducing pain behavior. Arthritis Res. Ther., 2020, 22: 34.

[157] Alimoradi N, Tahami M, Firouzabadi N, Haem E, Ramezani A. Metformin attenuates symptoms of osteoarthritis: role of genetic diversity of Bcl2 and CXCL16 in OA. Arthritis Res. Ther., 2023, 25: 35.

[158] Pan F, et al.. Metformin for knee osteoarthritis in patients with overweight or obesity: a randomized clinical trial. JAMA, 2025, 333: 1804-1812.

[159] Meurot C, et al.. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci. Rep., 2022, 12. ArticleID: 1567

[160] Que Q, et al.. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis. J. Inflamm., 2019, 16: 13.

[161] Vaittinen M, et al.. Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro. Diabetes Res. Clin. Pract., 2023, 199: 110635.

[162] Wu P, et al.. Liraglutide regulates mitochondrial quality control system through PGC-1α in a mouse model of Parkinson’s Disease. Neurotox. Res., 2022, 40: 286-297.

[163] Tong W, et al.. Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3–FOXO3a pathway. Hepatol. Res., 2016, 46: 933-943.

[164] Touceda V, et al.. Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet. Curr. Res. Pharmacol. Drug. Discov., 2024, 6: 100185.

[165] Gudbergsen H, et al.. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am. J. Clin. Nutr., 2021, 113: 314-323.

[166] Yang Y, et al.. Osteoarthritis treatment via the GLP-1-mediated gut-joint axis targets intestinal FXR signaling. Science, 2025, 388. ArticleID: eadt0548

[167] Meurot C, et al.. Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: a new opportunity?. J. Orthop. Translat., 2022, 32: 121-129.

[168] Nogueira-Recalde U, et al.. Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy. EBioMedicine, 2019, 45: 588-605.

[169] Grings M, et al.. Bezafibrate prevents mitochondrial dysfunction, antioxidant system disturbance, glial reactivity and neuronal damage induced by sulfite administration in striatum of rats: implications for a possible therapeutic strategy for sulfite oxidase deficiency. Biochim. Biophys. Acta Mol. Basis Dis., 2017, 1863: 2135-2148.

[170] Komen JC, Thorburn DR. Turn up the power – pharmacological activation of mitochondrial biogenesis in mouse models. Br. J. Pharmacol., 2014, 171: 1818-1836.

[171] Douiev L, Sheffer R, Horvath G, Saada A. Bezafibrate improves mitochondrial fission and function in DNM1L-deficient patient cells. Cells, 2020, 9: 301.

[172] Augustyniak J, et al.. Bezafibrate upregulates mitochondrial biogenesis and influence neural differentiation of human-induced pluripotent stem cells. Mol. Neurobiol., 2019, 56: 4346-4363.

[173] Zhao K, Luo G, Giannelli S, Szeto HH. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem. Pharmacol., 2005, 70: 1796-1806.

[174] Tan S, Sun Y, Li S, Wu H, Ding Y. The impact of mitochondrial dysfunction on osteoarthritis cartilage: current insights and emerging mitochondria-targeted therapies. Bone Res., 2025, 13: 77.

[175] Jávor P, et al.. Mitochondrial dysfunction affects the synovium of patients with rheumatoid arthritis and osteoarthritis differently. Int. J. Mol. Sci., 2022, 23: 7553.

[176] Bustamante MF, et al.. Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis. Ann. Rheum. Dis., 2018, 77: 1636-1643.

[177] Shen K, et al.. GATD3A-deficiency-induced mitochondrial dysfunction facilitates senescence of fibroblast-like synoviocytes and osteoarthritis progression. Nat. Commun., 2024, 15. ArticleID: 10923

[178] Van den Bossche, J. et al. Metabolic characterization of polarized M1 and M2 bone marrow-derived macrophages using real-time extracellular flux analysis. J. Vis. Exp. 105, 53424 (2015).

[179] Yang J, et al.. Targeting YAP1-regulated glycolysis in fibroblast-like synoviocytes impairs macrophage infiltration to ameliorate diabetic osteoarthritis progression. Adv. Sci., 2024, 11. ArticleID: e2304617

[180] Zhang L, et al.. Reprogramming mitochondrial metabolism in synovial macrophages of early osteoarthritis by a camouflaged meta-defensome. Adv. Mater., 2022, 34. ArticleID: e2202715

[181] Yuan Y-S, et al.. Reprogramming mitochondrial metabolism to enhance macrophages polarization by ROS-responsive nanoparticles for osteoarthritis. Biomaterials, 2025, 322: 123395.

[182] Suh J, et al.. Mitochondrial fragmentation and donut formation enhance mitochondrial secretion to promote osteogenesis. Cell. Metab., 2023, 35: 345-360.e7.

[183] Gao J, et al.. SIRT3/SOD2 maintains osteoblast differentiation and bone formation by regulating mitochondrial stress. Cell. Death. Differ., 2018, 25: 229-240.

[184] Kim H, Lee YD, Kim HJ, Lee ZH, Kim H-H. SOD2 and Sirt3 control osteoclastogenesis by regulating mitochondrial ROS. J. Bone. Miner. Res., 2017, 32: 397-406.

[185] Rambold AS, Kostelecky B, Elia N, Lippincott-Schwartz J. Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc. Natl. Acad. Sci. USA, 2011, 108: 10190-10195.

[186] Friedman JR, Nunnari J. Mitochondrial form and function. Nature, 2014, 505: 335-343.

[187] Wai T. Is mitochondrial morphology important for cellular physiology?. Trends Endocrinol. Metab., 2024, 35: 854-871.

[188] Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell. Death. Differ., 2013, 20: 31-42.

[189] Popov L-D. Mitochondrial biogenesis: an update. J. Cell. Mol. Med., 2020, 24: 4892.

[190] Nguyen TT, et al.. Mitochondria-associated programmed cell death as a therapeutic target for age-related disease. Exp. Mol. Med., 2023, 55: 1595-1619.

[191] Wang C, Youle RJ. The role of mitochondria in apoptosis. Annu. Rev. Genet., 2009, 43: 95.

[192] Nolfi-Donegan D, Braganza A, Shiva S. Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement. Redox. Biol., 2020, 37: 101674.

[193] Lee NH, Shapiro IM. Oxidative phosphorylation by chondrocyte mitochondria. Calcif. Tissue. Res., 1974, 16: 277-282.

[194] Cassidy-Stone A, et al.. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev. Cell, 2008, 14: 193-204.

[195] Qi X, Qvit N, Su Y-C, Mochly-Rosen D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J. Cell Sci., 2013, 126: 789-802

[196] D’Amico D, et al.. Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis. Aging. Cell., 2022, 21. ArticleID: e13662

[197] Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem., 1995, 229: 558-565.

[198] de Jesús García-Rivas G, Guerrero-Hernández A, Guerrero-Serna G, Rodríguez-Zavala JS, Zazueta C. Inhibition of the mitochondrial calcium uniporter by the oxo-bridged dinuclear ruthenium amine complex (Ru360) prevents from irreversible injury in postischemic rat heart. FEBS J., 2005, 272: 3477-3488.

[199] Thu LT, Ahn JR, Woo S-H. Inhibition of L-type Ca2+ channel by mitochondrial Na+-Ca2+ exchange inhibitor CGP-37157 in rat atrial myocytes. Eur. J. Pharmacol., 2006, 552: 15-19.

[200] Mishra J, et al.. Cyclosporin A increases mitochondrial buffering of calcium: an additional mechanism in delaying mitochondrial permeability transition pore opening. Cells, 2019, 8: 1052.

[201] Hou L, et al.. Mitoquinone alleviates osteoarthritis progress by activating the NRF2-Parkin axis. iScience, 2023, 26: 107647.

[202] Li Y, et al.. Mitochondrial-targeting and NIR-responsive Mn3O4@PDA@Pd-SS31 nanozymes reduce oxidative stress and reverse mitochondrial dysfunction to alleviate osteoarthritis. Biomaterials, 2024, 305: 122449.

[203] Bernardy CCF, et al.. Tempol, a superoxide dismutase mimetic agent, inhibits superoxide anion-induced inflammatory pain in mice. Biomed. Res. Int., 2017, 2017: 9584819.

[204] Failli P, et al.. A novel manganese complex effective as superoxide anion scavenger and therapeutic agent against cell and tissue oxidative injury. J. Med. Chem., 2009, 52: 7273-7283.

[205] Terabe K, et al.. Chondroprotective effects of 4-methylumbelliferone and hyaluronan synthase-2 overexpression involve changes in chondrocyte energy metabolism. J. Biol. Chem., 2019, 294: 17799-17817.

Funding

Agence Nationale de la Recherche (French National Research Agency)(ANR-18-CE14-0024-01)

KLOTHOA (ANR-18-CE14-0024-01)

Lucie Danet was a recipient of a fellowship from the French Ministry of Research.

RIGHTS & PERMISSIONS

The Author(s)